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Sir
Testicular cancer has a peak incidence among men aged 25 to 34
years, suggesting early life inﬂuences (Akre et al, 1996). The
hypothesis that exposure to endogenous or environmental oestro-
genic compounds affects embryonic testis and increases the risk
of testicular cancer has been put forth (Sharpe and Skakkeback,
1993). This intriguing hypothesis has acquired momentum and,
in fact, was invoked as the main aetiologic mechanism in a recent
major review (Dearnaley et al, 2001). If prenatal exposure to
oestrogens were indeed important, one would expect that popula-
tions with higher levels of pregnancy oestrogens would experience a
higher rate of testicular cancer. We have studied pregnancy
hormone levels, including oestrogen levels, in two populations with
very different rates of testicular cancer (Lipworth et al, 1999).
Adult pregnant women were recruited from maternity clinics of
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Pregnant women were enrolled during their ﬁrst prenatal visit to
the collaborating maternity clinic. Eligibility requirements included
that the pregnant women had to be less than 40 years old, had no
more than one previous stillborn or liveborn child, took no
hormonal medication during the index pregnancy and had no
prior diagnosis of diabetes mellitus or thyroid disease. Three
hundred and four Caucasian women in Boston and 335 Chinese
women in Shanghai were studied. Pregnancy serum concentrations
of oestradiol-17b (E2) and unconjugated oestriol (E3) were
measured in maternal blood at weeks 16 and 27 of gestation.
Details of the study have been published in this journal (Lipworth
et al, 1999). Levels of E2 and E3 were consistently and signiﬁcantly
higher among Chinese women at both sample 1 and sample 2
(Table 1). The age-standardised rate as well as age-speciﬁc inci-
dence rates of testicular cancer during the period of 1988–1992
for white and Chinese males (aged 15–49) were obtained from
the Connecticut and the Shanghai Cancer Registries, respectively
(Parkin et al, 1997). The rates for Chinese males in Shanghai at
all ages were much lower than those for white males in Connecti-
cut, despite evidence of exposure to higher levels of oestrogens in
utero.
While the hypothesis linking high oestrogen exposure with
testicular cancer and other disorders of the male reproductive
system is ingenious, empirical support so far has been limited.
Our data are incompatible with this hypothesis and, although
they do not conclusively refute it, tend to reduce its
plausibility.
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Table 1 Pregnancy serum concentrations of oestradiol (E2), and oestriol (E3) in Chinese women (Shanghai,
China) and Caucasian women (Boston, USA) (upper panel); age standardised and age-speciﬁc rates of testicular
cancer for Chinese and US males during 1988–1992 (lower panel)
Pregnancy oestrogen concentrations (nmol l
71, mean+s.d.), 1994–1995
(Lipworth et al, 1999)
Samples at 16th weeks of
gestation
Samples at 27th weeks of
gestation
E2 E3 E2 E3
Shanghai, China 20.7+9.7 6.3+3.9 48.2+18.3 21.9+9.5
Boston, US 14.0+6.4 3.9+1.7 39.1+16.6 14.0+4.4
Age-speciﬁc incidence rate of testicular cancer (per 100000), 1988–1992
(Parkin et al, 1997)
ASR 15–19 20–24 25–29 30–34 35–39 40–44 45–49
Shanghai, China 0.74 0.24 0.63 0.39 1.71 1.53 1.44 0.56
Connecticut, US, Whites 5.29 3.60 9.68 14.36 14.87 12.28 9.14 5.81
ASR: age standardised rate, adjusting all the age-speciﬁc rates in 5 year category (0–4, 5–9, ..., 80–84, 85+) to standard world
population (Parkin et al, 1997)
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